Multi-kinase-IN-5

Cat. No.: HY-149415

Molecular Formula: $C_{19}H_{15}N_5O_2S$

Molecular Weight: 377.42

Target: RET; FGFR; VEGFR; c-Kit; c-Met/HGFR; PDGFR; Raf

Pathway: Protein Tyrosine Kinase/RTK; MAPK/ERK Pathway

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitory agent. Multi-kinase-IN-5 inhibits a panel of protein kinases (RET, KIT, cMet, VEGFR1,2, FGFR1, PDGFR and BRAF), showing % inhibition of 74%, 31%, 62%, 40%, 73%, 74%, 59%, and 69%, respectively, and IC_{50} of 1.287, 0.117 and 1.185 μM against FGFR1, VEGFR, and RET kinases, respectively[1].			
IC_{50} & Target	FGFR1 1.287 μM (IC_{50})	VEGFR1	VEGFR2	Braf
	PDGFR			
In Vitro	Multi-kinase-IN-5 (compound 15c) shows active antiproliferative activity against most of the National Cancer Institute (NCI) 60 cancer cell lines with mean growth inhibition 61.83% and with IC_{50} values of 4.39, 1.06, and 0.34 nM against MCT-7, DU 145, and HCT-116 cell lines, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Ismail RSM, et al. Discovery of a new potent oxindole multi-kinase inhibitor among a series of designed 3-alkenyl-oxindoles with ancillary carbonic anhydrase inhibitory activity as antiproliferative agents. BMC Chem. 2023 Jul 18;17(1):81.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA